This article is more than 5 years old. Information may no longer be current.
eGlycemic Management System measures blood glucose, calculates personalized insulin dose
Click Here to Manage Email Alerts
A software program developed by Glytec will incorporate a patient’s blood glucose information and other factors to calculate an individualized insulin dose, helping patients with diabetes avoid the dangers of hypoglycemia and hyperglycemia, according to a company press release.
The U.S. Patent and Trademark Office has issued a Notice of Allowance for Glytec’s patent application for the eGlycemic Management System, a method for measuring a precise subcutaneous insulin dose. The software evaluates a patient's blood glucose levels and, coupled with other variables, including time of day and diet, calculates a personalized dose of insulin.
“Nearly 40% of patients admitted to acute care hospitals in the United States experience hyperglycemia and some 10% hypoglycemia, and there are hundreds of thousands of emergency room visits and hospitalizations each year related to glucose control that could be avoided, Andrew S. Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC, chief medical officer for Glytec, said in a press release. “Providers and patients have long experienced the ineffectiveness of sliding scale and paper protocols. Our unique insulin administration method and glycemic management decision support system enables them to take advantage of the growing availability of actionable data and stage appropriate interventions safely, effectively and efficiently across the continuum of care.”
The subcutaneous insulin treatment covers several different insulin delivery modules, including one or more of a standard subcutaneous module, a subcutaneous module without meal boluses, a meal-by-meal subcutaneous module without carbohydrate counting, a meal-by-meal subcutaneous module with carbohydrate counting, and a subcutaneous module for people without diabetes.
The standard subcutaneous program includes calculating an individualized insulin dose based on a patient’s blood glucose values, time of day, as well as other attributes specific to a particular blood glucose measurement. Methods to calculate personalized correction doses of insulin are also described.
Bob Leonard, president and CEO of Glytec, said recent studies show the glycemic management software helped both patients and providers.
“There have been 47 studies published to date concerning our system and 28 more studies are in process, including a just completed remarkable 60,000-plus patient study focused on hypoglycemia to be published next year, collectively validating the overwhelming impact of our patient-centered technologies on quality and cost,” Leonard said in a press release.